200 related articles for article (PubMed ID: 31523805)
1. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
[TBL] [Abstract][Full Text] [Related]
2. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
[TBL] [Abstract][Full Text] [Related]
3. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
[TBL] [Abstract][Full Text] [Related]
4. Prediagnostic immunoglobulin E levels and risk of chronic lymphocytic leukemia, other lymphomas and multiple myeloma-results of the European Prospective Investigation into Cancer and Nutrition.
Nieters A; Łuczyńska A; Becker S; Becker N; Vermeulen R; Overvad K; Aleksandrova K; Boeing H; Lagiou P; Trichopoulos D; Trichopoulou A; Krogh V; Masala G; Panico S; Tumino R; Sacerdote C; Bueno-de-Mesquita B; Jeurnink SM; Weiderpass E; Ardanaz E; Chirlaque MD; Sánchez MJ; Sánchez S; Borgquist S; Butt S; Melin B; Späth F; Rinaldi S; Brennan P; Kelly RS; Riboli E; Vineis P; Kaaks R
Carcinogenesis; 2014 Dec; 35(12):2716-22. PubMed ID: 25269801
[TBL] [Abstract][Full Text] [Related]
5. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
[TBL] [Abstract][Full Text] [Related]
6. Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts.
Bassig BA; Shu XO; Koh WP; Gao YT; Purdue MP; Butler LM; Adams-Haduch J; Xiang YB; Kemp TJ; Wang R; Pinto LA; Zheng T; Ji BT; Hosgood HD; Hu W; Yang G; Zhang H; Chow WH; Kim C; Seow WJ; Zheng W; Yuan JM; Lan Q; Rothman N
Int J Cancer; 2015 Dec; 137(11):2688-95. PubMed ID: 26095604
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.
Abuamsha H; Kadri AN; Hernandez AV
Hematol Oncol; 2019 Aug; 37(3):261-269. PubMed ID: 30916804
[TBL] [Abstract][Full Text] [Related]
8. Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma.
Zhang Y; Sanjose SD; Bracci PM; Morton LM; Wang R; Brennan P; Hartge P; Boffetta P; Becker N; Maynadie M; Foretova L; Cocco P; Staines A; Holford T; Holly EA; Nieters A; Benavente Y; Bernstein L; Zahm SH; Zheng T
Am J Epidemiol; 2008 Jun; 167(11):1321-31. PubMed ID: 18408225
[TBL] [Abstract][Full Text] [Related]
9. Insecticide use and risk of non-Hodgkin lymphoma subtypes: A subset meta-analysis of the North American Pooled Project.
Kachuri L; Beane Freeman LE; Spinelli JJ; Blair A; Pahwa M; Koutros S; Hoar Zahm S; Cantor KP; Weisenburger DD; Pahwa P; Dosman JA; McLaughlin JR; Demers PA; Harris SA
Int J Cancer; 2020 Dec; 147(12):3370-3383. PubMed ID: 32574374
[TBL] [Abstract][Full Text] [Related]
10. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.
Makgoeng SB; Bolanos RS; Jeon CY; Weiss RE; Arah OA; Breen EC; Martínez-Maza O; Hussain SK
JNCI Cancer Spectr; 2018 Dec; 2(4):pky082. PubMed ID: 30873511
[TBL] [Abstract][Full Text] [Related]
11. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.
Breen EC; Hussain SK; Magpantay L; Jacobson LP; Detels R; Rabkin CS; Kaslow RA; Variakojis D; Bream JH; Rinaldo CR; Ambinder RF; Martinez-Maza O
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1303-14. PubMed ID: 21527584
[TBL] [Abstract][Full Text] [Related]
12. Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.
Hussain SK; Hessol NA; Levine AM; Breen EC; Anastos K; Cohen M; D'Souza G; Gustafson DR; Silver S; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2084-93. PubMed ID: 24045923
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.
Levin LI; Ramirez CM; Liao EL; Guo H; Kim BK; Marrogi AJ; Magpantay LI; Breen EC; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):233-241. PubMed ID: 36409490
[TBL] [Abstract][Full Text] [Related]
14. Occupational exposure to trichloroethylene is associated with a decline in lymphocyte subsets and soluble CD27 and CD30 markers.
Lan Q; Zhang L; Tang X; Shen M; Smith MT; Qiu C; Ge Y; Ji Z; Xiong J; He J; Reiss B; Hao Z; Liu S; Xie Y; Guo W; Purdue MP; Galvan N; Xin KX; Hu W; Beane Freeman LE; Blair AE; Li L; Rothman N; Vermeulen R; Huang H
Carcinogenesis; 2010 Sep; 31(9):1592-6. PubMed ID: 20530238
[TBL] [Abstract][Full Text] [Related]
15. Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis.
Späth F; Wibom C; Krop EJ; Johansson AS; Bergdahl IA; Vermeulen R; Melin B
Cancer Res; 2017 Mar; 77(6):1408-1415. PubMed ID: 28108506
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
Purdue MP; Lan Q; Martinez-Maza O; Oken MM; Hocking W; Huang WY; Baris D; Conde B; Rothman N
Blood; 2009 Sep; 114(13):2730-2. PubMed ID: 19638620
[TBL] [Abstract][Full Text] [Related]
17. Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.
Saberi Hosnijeh F; Kolijn PM; Casabonne D; Nieters A; Solans M; Naudin S; Ferrari P; Mckay JD; Weiderpass E; Perduca V; Besson C; Mancini FR; Masala G; Krogh V; Ricceri F; Huerta JM; Petrova D; Sala N; Trichopoulou A; Karakatsani A; La Vecchia C; Kaaks R; Canzian F; Aune D; Boeing H; Schulze MB; Perez-Cornago A; Langerak AW; van der Velden VHJ; Vermeulen R
Sci Rep; 2020 Aug; 10(1):13814. PubMed ID: 32796953
[TBL] [Abstract][Full Text] [Related]
18. Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study.
Kleinstern G; Camp NJ; Berndt SI; Birmann BM; Nieters A; Bracci PM; McKay JD; Ghesquières H; Lan Q; Hjalgrim H; Benavente Y; Monnereau A; Wang SS; Zhang Y; Purdue MP; Zeleniuch-Jacquotte A; Giles GG; Vermeulen R; Cocco P; Albanes D; Teras LR; Brooks-Wilson AR; Vajdic CM; Kane E; Caporaso NE; Smedby KE; Salles G; Vijai J; Chanock SJ; Skibola CF; Rothman N; Slager SL; Cerhan JR
Cancer Epidemiol Biomarkers Prev; 2020 May; 29(5):1074-1078. PubMed ID: 32108027
[TBL] [Abstract][Full Text] [Related]
19. Racial differences in three major NHL subtypes: descriptive epidemiology.
Li Y; Wang Y; Wang Z; Yi D; Ma S
Cancer Epidemiol; 2015 Feb; 39(1):8-13. PubMed ID: 25560974
[TBL] [Abstract][Full Text] [Related]
20. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
Morton LM; Curtis RE; Linet MS; Bluhm EC; Tucker MA; Caporaso N; Ries LA; Fraumeni JF
J Clin Oncol; 2010 Nov; 28(33):4935-44. PubMed ID: 20940199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
